(thirdQuint)A Study to Assess the Efficacy and Safety of Ipragliflozin in Combination With Insulin in Subjects With Type 2 Diabetes Mellitus.

 This study consists of two parts.

 First part is a placebo-controlled multicenter, double-blind, parallel group study, in which subjects will receive ipragliflozin or placebo once daily in combination with an insulin preparation for 16 weeks.

 Second part is a multicenter, open-label period (36 weeks) with no placebo group.

 The dose of ipragliflozin can be doubled in combination with an insulin preparation during the second part.

.

 A Study to Assess the Efficacy and Safety of Ipragliflozin in Combination With Insulin in Subjects With Type 2 Diabetes Mellitus@highlight

The purpose of this study is to assess the efficacy (superiority to placebo) of ipragliflozin based on the changes in HbA1C, as well as its safety, in patients with type 2 diabetes mellitus in combination with an insulin preparation once daily for 16 weeks.

 The long-term (52 weeks) safety and the persistence of the efficacy will also be evaluated.

